Methodologies for in silico and in vitro Test of Biphenylalanine Compounds as Potential HIV-1 gp120 Attachment Inhibitors

Authors

  • SK. Md. Jakaria Al-Mujahidy Microbiologist, Medimet Pharmaceuticals Ltd., Barisal, Bangladesh

DOI:

https://doi.org/10.37591/(rrjobi).v2i3.392

Abstract

We postulate that biphenylalanine and its derivatives are propitious candidates to inhibit the binding of HIV-gp120 to CD4 T-cell. Many biphenylalanine derivatives are synthesized chemically and also prevailing in nature. We have proposed atom- and bond-based 2D TOMOCOMD-CARDD approach to identify the best derivative. Moreover, according to our proposition, the principal law simulated from in silico interaction of gp120 with CD4 can be tested by ELISA in vitro. Furthermore, the toxicity of biphenylalanine compounds might be evaluated using MTT cytotoxicity test kits for future development of attachment inhibitors in vivo. It will be a novel idea to determine the efficacy of biphenylalanine compounds as a drug. To determine, in advance the possible stable mutation forms (all mutations are not stable) around the apolar ‘Phe43 cavity’ on gp120 and predict the next generation drugs against these mutations we opine to develop a discriminated function of local (amino acid-type) linear indices of the “macromolecular pseudograph’s α-carbon atom adjacency matrix”- that permits the classification of mutants as near wild type stability or reduced stability. To sum up, the consummate biphenylalanine substances will likely to be an ace in a hole for millions of people worldwide.

 

Keywords: Biphenylalanine compounds, HIV-1 gp120, CD4 T-cell, HIV

Cite this Article

Al-Mujahidy SK. Md. Jakaria. Methodologies for in silico and in vitro test of biphenylalanine compounds as potential HIV-1 gp120 attachment inhibitors. Research & Reviews: A Journal of Bioinformatics. 2015; 2(3): 38–42p.

Downloads

Published

2019-03-18

Issue

Vol. 2 No. 3 (2015)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.